August 17, 2017
Rapid-Fire Approvals and a "Living Document" Guidance Document
The two medical associations responsible for crafting HCV treatment guidelines are the American Association for the Study of Liver Disease (AASLD) and the Infectious Disease Society of America (IDSA). Together, these associations have crafted what they call a "living document," which is posted online and updated continually to reflect the rapidly changing treatment landscape. Still, as of August 2017, some newer drugs such as sofosbuvir/velpatasvir/voxilaprevir had not been incorporated into the document.
Yet, despite the rapid-fire approvals, almost all of the prior guidance holds true. For example, the guidelines recommend treatment for all HCV-infected people, except in extreme circumstances such as terminal illness. In addition, the guidelines no longer recommend daily sofosbuvir (Sovaldi) with ribavirin or pegylated interferon (even in combination) due to the plethora of better alternatives now available.
Image credit: Comstock for Stockbyte via Thinkstock.
|The Need for a Codified Hepatitis C Care Continuum|
|Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|